Rectal cancer patient who participated in the trial saw their disease vanish
A clinical trial done by Memorial Sloan Kettering Cancer Center made a delightful discovery. 18 cancer patients who took the drug Dostarlimab found that their cancer had vanished. The trial discovered that every single rectal cancer patient who participated in the trial saw their disease vanish. According to the New York Times, 18 patients took a medicine named Dostarlimab for six months, and all of them saw their tumors shrink. Individuals in the clinical experiment previously received chemotherapy, radiation, and invasive surgery, all of which caused bowel, urinary, and sexual dysfunction. The 18 patients were expected to have to go through surgeries as the next step in the research. However, they were surprised that no more therapy was required.
Dr. Alan P. Venook, the colorectal cancer specialist at the University of California, said that every patient's complete remission is "unheard-of." The study is praiseworthy as not all the participants experienced severe side effects. According to doctors, the patients took Dostarlimab every three weeks for six months. At the time of this report, no patients had undergone chemo radiotherapy or surgery, and no cases of progression or recurrence of cancer had been reported during follow-up. Cancer researchers find the drug promising and want more extensive trials to be conducted.